Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
Prostate Cancer Prostatic Dis
.
2022 Apr;25(4):804.
doi: 10.1038/s41391-022-00578-7.
Authors
Scott T Tagawa
1
,
Krishnan Ramaswamy
2
,
Ahong Huang
3
,
Jack Mardekian
4
,
Neil M Schultz
5
,
Li Wang
3
,
Rickard Sandin
6
,
Stanislav Lechpammer
7
,
Daniel J George
8
Affiliations
1
Weill Cornell Medicine, New York, NY, USA.
2
Pfizer Inc., New York, NY, USA. krishnan.ramaswamy@pfizer.com.
3
STATinMED Research, Plano, TX, USA.
4
Pfizer Inc., New York, NY, USA.
5
Astellas Pharma Inc., Northbrook, IL, USA.
6
Pfizer AB., Sollentuna, Sweden.
7
Pfizer Inc., San Francisco, CA, USA.
8
Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
PMID:
35840724
PMCID:
PMC9705240
DOI:
10.1038/s41391-022-00578-7
No abstract available
Publication types
Published Erratum